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OBJECTIVE: In this study, the relationship between osteoporotic vertebral fractures and 9041 Guanine/Adenine
and 3673 Guanine/Adenine polymorphisms related to the vitamin K epoxide reductase complex subunit-1
(VKORC1) gene in postmenopausal women with osteoporosis was investigated.
METHOD: DNA was isolated from blood samples collected from 150 women with postmenopausal osteoporosis.
Genotyping of the two polymorphic regions (9041 Guanine/Adenine and 3673 Guanine/Adenine) in VKORC1 was
performed using polymerase chain reaction–restriction fragment length polymorphism analysis. The presence of
radiographic fractures among the 150 patients was ascertained by using the Genant method.
RESULT: At least one fracture was detected in 98 patients, and no fracture was observed in 52 patients on
radiological images. We found no association between the 9041 Guanine/Adenine (p=0.283) and 3673 Guanine/
Adenine (p=0.232) polymorphisms of the VKORC1 gene and the development of secondary postosteoporotic
fractures in our study.
CONCLUSION: There was no relationship between osteoporotic vertebral fracture and VKORC1 gene poly-
morphism in a postmenopausal Turkish population.
KEYWORDS: Osteoporosis; Polymorphism; Vitamin K Epoxide Reductase Complex Subunit-1 Gene; Vertebral
Fracture.
’ INTRODUCTION
Osteoporosis is a disease that causes general health pro-
blems associated with low bone mass and microarchitectural
damage in bone tissue. These changes in bone structure
cause increased bone fragility and fracture susceptibility (1).
The increased prevalence of osteoporosis-associated fractures
with increased life span has resulted in lower quality of life,
disability and even death (2). Environmental factors such as
nutritional and genetic factors play an important role in
osteoporosis (3,4).
According to recent studies, vitamin K could be associated
with bone metabolism and may provide protection against
fractures (5-8). Vitamin K is a co-factor that involves many
biochemical pathways related to carboxylation reactions (9).
The carboxylation of osteocalcin, which is an important bone
matrix protein, depends on vitamin K. Vitamin K epoxide
reductase complex subunit 1 (VKORC1) enzyme activity is
necessary for the effect of vitamin K on bone metabolism
(9-11). In humans, the VKORC1 gene is found in the 16p11.2
region of the chromosome, coding a 163-amino acid protein
with a molecular weight of 18 kDa (12). In the VKORC1 gene,
many single nucleotide polymorphisms (SNPs) have been
identified, including SNPs 1173 (6484) C/T (rs9934438) in
intron 1, 9041 (3730) Guanine (G)/Adenine (A) (rs7294) in
the 30-untranslated region and 3673 (1639) G/A (rs9923231)
in the promoter (13).
Many reports on vitamin K treatment in osteoporosis and
related fractures have been published (7,14-16). However,DOI: 10.6061/clinics/2019/e739
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there have been few studies on the association between
osteoporosis and polymorphisms of the VKORC1 enzyme
(11,17). In addition, in the literature, there are no studies on
the relationship between genetic variations in the VKORC1
gene and bone mineral density (BMD) and osteoporotic
fractures in the Turkish population.
Determination of the association of some vitamin K-related
polymorphisms with osteoporosis and osteoporosis fractures
could be used for clinical prevention and the planning of
individual treatment targets. Therefore, we aimed to investi-
gate VKORC1 9041 G/A and 3673 G/A polymorphisms that
varied among populations in osteoporosis and postosteo-
porotic vertebral fractures in Turkish women with postmen-
opausal osteoporosis.
’ MATERIALS AND METHODS
Subjects
This study included 150 female patients with postmeno-
pausal osteoporosis.
Inclusion Criteria
Thoracal and lumbar lateral radiographs and double ener-
getic X-ray absorptiometry (DXA) results of female patients
with postmenopausal osteoporosis were retrospectively anal-
yzed in Physical Therapy and Rehabilitation clinics of Eskisehir
Osmangazi University. Patients with normal complete blood
count, calcium, phosphorus, erythrocyte sedimentation rate,
serum alkaline phosphatase, vitamin D, glucose, aspartate
aminotransferase, albumin, alanine aminotransferase, gamma-
glutamyl transpeptidase, uric acid, urea nitrogen, blood
creatinine, urine calcium creatinine ratio, parathyroid hor-
mone, thyroid-stimulating hormone and cortisol levels were
included in this study.
Exclusion Criteria
Patients with a history of traumatic fractures, surgical
menopause, or medical conditions that have a potential effect
on bone metabolism (e.g., parathyroid, thyroid, liver or rheu-
matic disease or malignancy) or drug use (corticosteroids,
anticonvulsants, heparin, etc.) were excluded from the clini-
cal evaluation.
At least one fracture was detected in 98 patients, and no
fracture was observed in 52 patients on radiological images.
Body mass index (BMI) and age were recorded. The working
procedures have been approved in writing by Eskis¸ehir
Osmangazi University Faculty of Medicine Ethics Committee
(no. 2009/229). The DNA samples collected for the study
were used in accordance with the decision of the ethics
committee no. 2012/103.
Bone Mineral Density (BMD) Measurement
DXA (Hologic QDR, 4500 W) was used to measure bone
density in the lumbar vertebral and femoral bone (femur
neck, trochanter and Ward triangle). Bone density test results
were evaluated as T-scores and Z-scores. According to WHO
recommendations, patients with a T-score below -2.5 of the
young adult mean value standard deviation were classified
as osteoporosis (18).
Radiographic Assessment
The presence of radiographic fractures among the
150 patients was ascertained by using the Genant method.
In this method, the rate of the decrease in the middle and/or
posterior height of T4-L4 vertebrae in the lateral spinal X-rays
(Shimadzu, RADspeed PRO, MO2ABC775003/TAEK13136,
Japan) was used. Fracture presence was indicated by loss of
height in at least one vertebra between T4 and L4 in lateral
spinal radiography (19).
Sample Collection
Blood samples (10 mL) were obtained from all subjects for
genomic DNA extraction using the salt extraction method
(20). The collected genomic DNA samples were kept at 4oC.
The purity and amount of isolated DNA samples were mea-
sured by spectrophotometry (ASP 3700, ACTGene, Piscat-
away, NJ, USA).
Determination of VKORC1 Genotypes
9041 G/A and 3673 G/A VKORC1 polymorphisms were
determined using polymerase chain reaction–restriction frag-
ment length polymorphism (PCR–RFLP) analysis. Briefly,
isolated DNA samples were amplified using Taq DNA poly-
merase (Thermo Scientific, California, USA) and the specific
primers for the VKORC1 polymorphisms (Table 1) in poly-
merase chain reaction (PCR) (Sacem Life Technologies,
Peltier based Thermal Cycler SCM 96G, Turkey). The PCR
conditions are shown in Table 1. Approximately 0.5 ml of
DNA sample was amplified using a 25 ml PCR mixture
containing 2.5 pmol from each primer, 1x PCR buffer with
magnesium chloride (New England BioLabs, Ipswich, Uni-
ted Kingdom), 0.2 mM dNTPs, and 0.5 U Taq polymerase
(New England BioLabs, Ipswich, United Kingdom). Follow-
ing amplification, PCR products were digested by restriction
enzymes. The 674-bp VKORC1 9041 G/A fragment was
digested with AciI (New England BioLabs, Ipswich, United
Kingdom) in a 25 ml reaction containing 10 ml PCR fragment,
2.5 ml Reaction Buffer (NEBuffer 3) (New England BioLabs,
Ipswich, United Kingdom), 12 ml PCR grade water and 0.5 ml
AciI at 37oC for 1 h. The 636-bp VKORC1 3673 G/A fragment
was digested with NciI (New England BioLabs, Ipswich,
United Kingdom) in a 25 ml reaction containing 10 ml PCR
fragment, 2.5 ml Reaction Buffer (NEBuffer 4) (New England
BioLabs, Ipswich, United Kingdom), 12.4 ml PCR grade water
and 0.1 ml of NciI at 37oC for 1h. The digested products were
analyzed for the presence or absence of recognition sites
by SYBRs Safe DNA gel stain (Invitrogen, Paisley, United
Kingdom) of fragments separated through a 2% agarose gel
and analyzed under UV light (Synegene Gene Genius Gel
Light Imaging System, Cambridge, United Kingdom).
Digested patterns belonging to the 674 bp amplicon of
9041 G/A SNP and the 636 bp amplicon of the VKORC1
3673 G/A SNP are shown in Table 1.
Statistical Analysis
Statistical analyses were calculated by using IBM SPSS
Statistics 21.0 (SPSS Inc., Chicago, IL, USA). Descriptive
statistics are displayed as the mean ± standard deviation
(SD) and median (%25, %75) for continuous variables and
number and percentage with characteristics for categorical
variables. Pearson chi-square analysis was used for catego-
rical variables. Multiple logistic regression analysis was
performed for 9041 G/A and 3673 G/A in postmenopausal
osteoporosis patients with and without fractures. The results
of analysis, odds ratio (OR) and a 95% confidence interval
(CI) are displayed. All p-values o0.05 were accepted as
statistically significant.
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’ RESULTS
A total of 150 female patients with postmenopausal
osteoporosis were included in the study to investigate the
relationship between postosteoporotic spinal fractures and
the distribution of 9041 G/A and 3673 G/A polymorph-
isms in the VKORC1 gene. In our study, the mean age of
women with postmenopausal osteoporosis was 61.78±8.11,
the mean BMI was 27.78±4.19, the mean T score in the
femoral neck was -2.93±0.41, and the mean T score in the
lumber vertebrae was -2.83±0.75. Radiographic assess-
ments showed the presence of at least one fracture in 98
patients with osteoporosis.
There was no relationship between the VKORC1 9041
G/A polymorphism and allele frequency in patients with
and without postmenopausal osteoporosis (p=0.283, p=0.221).
However, the mutant A allele frequency was decreased in
67 (34.18%) postmenopausal women with osteoporosis and
fractures compared with that in 129 (41.35%) patients with no
fractures (Table 2). In patients with vertebral fractures com-
pared with those with no fractures, the frequency of the AA
allele was 1.73 times smaller than that of the GG allele.
However, this increase was not statistically significant
(OR=0.568, 95% CI 0.276, 1.158 p=0.120) (Table 3).
Similar to the 3673 G/A polymorphism and allele fre-
quency, the genotype distribution of this polymorphism also
did not differ between patients with osteoporosis with or
without fractures (p=0.232, p=0.851). However, the mutant
A allele frequency was decreased in 104 (53.06%) postmeno-
pausal women with osteoporosis with fractures compared
with that in 92 (51.92%) patients with no fractures (Table 2).
In patients with vertebral fractures compared with patients
with no fractures, the frequency of the AA allele was 1.535
times higher than that of the GG allele. However, this
increase was nonsignificant (OR=1.533, 95% CI 0.723, 0.271,
p=0.266) (Table 3).
Table 1 - PCR protocols and primer sequences for amplification of different loci of the vitamin K reductase complex subunit 1
(VKORC1) gene.
Loci Primers Size and fragments PCR protocol
9041 G/A F-50-TTTAGAGACCCTTCCCAGCA -30
R-50-AGCTCCAGAGAAGGCAACAC-30
674 bp GG 117 bp
216 bp
341 bp
95oC for 30 s
59oC for 1 min







3673 G/A F- 50-ATCCCTCTGGGAAGTCAAGC-30
R- 50-CACCTTCAA CCTCTCCATCC-30
636 bp GG 50 bp
114 bp
472 bp
95oC for 30 s
60oC for 1 min







A Adenine, G Guanine, C Cytosine, T Thymine.
Table 2 - 9041 G/A and 3673 G/A genotype and allele frequency distribution in postmenopausal osteoporosis patients with and
without fracture.
Genotype Postmenopausal Patients with Osteoporosis p values
Without Fracture (n=52) With Fracture (n=98)
9041 G/A GG 16 (31%) 43 (44%) 0.283
GA 29 (56%) 43 (44%)
AA 7 (13%) 12 (12%)
Allele frequency G 61 (58.6%) 129 (41.35%) 0.221
A 43 (41.35%) 67 (34.18%)
3673 G/A GG 16 (30.8%) 22 (22.4%) 0.232
GA 18 (34.6%) 48 (49%)
AA 18 (34.6%) 28 (28.6%)
Allele frequency G 50 (48.08%) 92 (96.94%) 0.851
A 54 (51.92%) 104 (53.06%)
A Adenine, G Guanine, C Cytosine, T Thymine.
Table 3 - 9041 G/A and 3673 G/A in postmenopausal patients
with osteoporosis with and without fracture.
Genotype OR (95% Cl) p values
9041 G/A GG 1 (reference) 0.120
AA+GA 0.568 (0.279-1.158)
3673 G/A GG 1 (reference) 0.266
AA+GA 1.535 (0.721-3.271)
A Adenine, G Guanine, C Cytosine, T Thymine.
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’ DISCUSSION
The genetic factors of osteoporosis are important for under-
standing the diagnosis and development of new treatment
methods. In studies that investigated the genetic basis of
osteoporosis and osteoporotic fractures, several candidate
genome-wide association studies (GWAS) have been per-
formed, and SNPs, which may be associated with the deve-
lopment of osteoporosis, have been identified (21-25).
Based on previous studies, the VKORC1 haplotype profile
varies between large populations of different origins (26).
Moreover, considering that BMD distribution varies per popu-
lation, genetic variants of the VKORC1 gene may be asso-
ciated with BMD and osteoporosis. The 3673 G/A and 1173
C/T SNPs of the VKORC1 SNP genotype have been asso-
ciated with higher BMD values, while polymorphisms in
VKORC1 (rs8050894 and rs2884737) are related to reduced
BMD. Furthermore, the association between VKORC1 and
BMD reportedly exhibits certain variations according to popu-
lations (17). In studies that have investigated the association
between BMD, atherosclerosis and VKORC1 1173 C4T poly-
morphisms in patients with osteoporosis or osteopenia, a high
frequency of the TT genotype has been found in VKORC1
1173 C4T polymorphisms. The TT genotype is more common
in the osteoporotic group than in the osteopenic group, and
the TT genotype of VKORC1 1173 C4T could be a potential
genetic marker for osteoporosis (27). The effect of VKORC1
polymorphisms on BMD and fractures was analyzed in a pilot
study. In that study, genotyping for VKORC1 3673 G/A or
9041 G/A derivatives was performed using allele-specific PCR
in 149 of the 184 individuals, and an association was obser-
ved between genotypes and clinical parameters. Significantly
high levels of 9041 GG and GA were detected in patients
with low BMD (p=0.012). Therefore, a higher risk of low
BMD was identified for individuals carrying at least 1 G
allele. No significant correlation was found between the 3673
G/A derivative and BMD, and none of the variants were
associated with fractures. In this study, genetic variation in
the 30 locations of the VKORC1 gene (9041 AG and GG) was
correlated with significantly reduced BMD. Therefore, genetic
variations may have an important role in osteoporosis. In our
study, the association of the VKORC1 gene polymorphisms
with both osteoporosis and osteoporotic fractures was exam-
ined. In our study, similar to the study by Holzer et al. (11), the
relationship between the development of osteoporosis and the
9073 G/A and 3673 G/A polymorphisms of the VKORC1
gene were investigated, and no correlation was found between
these polymorphisms. In addition, there was no correlation
between 9073 G/A and 3673 G/A polymorphisms and
vertebral fractures associated with postmenopausal osteo-
porosis in our study.
Our study has several limitations that must be considered.
The number of patients in our study was small in terms of
statistical power analysis. There were no data on the distri-
bution of VKORC1 9041 G/A and 3673 G genotypes in a
Turkish population. In addition, there was insufficient infor-
mation on the nutritional patterns and blood vitamin K
levels that may be associated with osteoporotic vertebral
fractures in female patients with postmenopausal osteoporo-
sis. To our best knowledge, this study is the first to inves-
tigate the relation between VKORC1 genotypes and vertebral
fracture among postmenopausal women in the literature and
Turkish society.
’ CONCLUSION
Genetic studies with patients with osteoporosis may allow
the development of new strategies for the widely available
therapeutic agents or the identification of target molecules
for new therapeutic agents. The present study was planned
to demonstrate a possible relationship between vertebral
fracture and polymorphisms of the VKORC1 gene in osteo-
porosis. As a result of this study, there was no relationship
between osteoporotic vertebral fracture and VKORC1 gene
polymorphism in a postmenopausal Turkish population.
According to the results of the logistic regression analysis of
our study, if the number of patients was increased, there may
be a relationship in terms of alleles. For this reason, there is a
need for multicenter studies with wider populations, includ-
ing all osteoporosis subgroups.
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